Skip to main content
Equibles

ASND · Ascendis Pharma A/S · Metrics

Track ASND — free

Use ASND with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ASND.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$227.83 -0.24 (-0.11%) At close · Sep 30
Russell 1000 member Rebalance outlook locked
Market Cap
$15.03B
Shares
65.78M
Volume · Sep 30 926.23K Avg daily vol (3M) 641.12K

ASND metrics

67 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$227.83
Market cap
$15.03B

Price action

20 metrics
Price change (1W)
-4.0%
Price change (30D)
-13.3%
Price change (3M)
-14.5%
Price change (6M)
-0.3%
Price change (YTD)
+7.0%
Price change (1Y)
+19.0%
Trailing year
Price change (5Y)
+45.3%
52-week high
$277.18
52-week low
$191.60
Change from 52-week high
-17.7%
Change from 52-week low
+19.0%
Annualized volatility
39.2%
Annualized volatility (3M)
37.6%
Beta
0.3
RSI (14D)
37.7
Price vs SMA 50
-8.9%
Price vs SMA 200
-3.1%
Avg volume (3M)
636,501
Relative volume
1.2
Average dollar volume
$160.15M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
65.78M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
12.3×
reciprocal yield 8.1%
P / book
9.2
reciprocal yield 10.9%
FCF yield
—
TTM · current market cap
Buyback yield
0.8%
P / FCF
—
P / operating cash flow
36.9
reciprocal yield 2.7%
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.8%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-13

Profitability

9 metrics
Gross margin
91.3%
Operating margin
25.4%
Trailing 12 months
Net margin
70.8%
Gross profit (TTM)
$955.89M
Operating profit (TTM)
$266.17M
Net income (TTM)
$865.26M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
-658.1%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-2.63

Growth

11 metrics
Revenue growth YoY
+114.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.22B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.1%
Year over year · more shares
Revenue CAGR (3Y)
+141.4%
Revenue CAGR (5Y)
+153.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
51.6%
Return on assets
32.4%
Debt / equity
—
Current ratio
3.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
2.3
Interest coverage
1.4
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$927.36M
Latest balance sheet
Cash & equivalents
$927.36M
Total assets
$2.61B
Total debt
$845.30M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$407.70M
Capital expenditures (TTM)
$1.02M
R&D (TTM)
$326.57M
SG&A (TTM)
—
Stock compensation (TTM)
$140.63M
R&D / revenue
26.7%
Stock compensation / revenue
11.5%

Ownership (13F)

3 metrics
13F filers
315
13F filer change QoQ
+32
Institutional ownership
102.9%

Short interest

3 metrics
Short interest
6.0%
Latest settlement · 4.9 days to cover
Days to cover
4.9d
Short-squeeze score
55 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$380,251
Insider-sentiment score
50 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1612042 CUSIP K08588103 13F (30d) 8 filings 8 filers Visit website Investor relations